COL18A1 and hepatocellular carcinoma: Its N-terminal RGDRGD fragment can specifically bind to different integrins in endothelial cells, which has been shown to have anti-tumor effects in colorectal cancer, oral squamous cell carcinoma and hepatocellular carcinoma (HCC).315,316 Based on the “one drug and two targets” design, Yang et al. selected the anti-tumor active fragment of endostatin and carried out structural modification and optimization on this basis, so that it could not only inhibit vascular activity, but also further have de-integrin effect.